Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
62.35
-0.84 (-1.33%)
Mar 31, 2025, 9:38 AM EDT - Market open
Haemonetics Revenue
Haemonetics had revenue of $348.54M in the quarter ending December 28, 2024, with 3.66% growth. This brings the company's revenue in the last twelve months to $1.37B, up 8.14% year-over-year. In the fiscal year ending March 30, 2024, Haemonetics had annual revenue of $1.31B with 12.01% growth.
Revenue (ttm)
$1.37B
Revenue Growth
+8.14%
P/S Ratio
2.33
Revenue / Employee
$375,585
Employees
3,657
Market Cap
3.13B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 30, 2024 | 1.31B | 140.40M | 12.01% |
Apr 1, 2023 | 1.17B | 175.46M | 17.67% |
Apr 2, 2022 | 993.20M | 122.73M | 14.10% |
Apr 3, 2021 | 870.46M | -118.02M | -11.94% |
Mar 28, 2020 | 988.48M | 20.90M | 2.16% |
Mar 30, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Apr 1, 2017 | Pro | Pro | Pro |
Apr 2, 2016 | Pro | Pro | Pro |
Mar 28, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HAE News
- 27 days ago - Haemonetics Announces Executive Leadership Updates - PRNewsWire
- 5 weeks ago - Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference - PRNewsWire
- 7 weeks ago - Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website - PRNewsWire
- 2 months ago - Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A - PRNewsWire
- 2 months ago - Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025 - PRNewsWire
- 3 months ago - Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 months ago - Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A - PRNewsWire